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Background: The renin-angiotensin-aldosterone system (RAAS) plays an important role in the progression of
chronic kidney disease (CKD). Although dual RAAS inhibition results in worse renal outcomes than monotherapy in
high risk type 2 diabetes patients, the effect of dual RAAS inhibition in patients with non-DM CKD is unclear. The
aim of this study was to evaluate the potential renoprotective effect of add-on direct renin inhibitor in non-DM
CKD patients.
Methods: We retrospectively enrolled 189 non-DM CKD patients who had been taking angiotensin II receptor
blockers (ARBs) for more than six months. Patients were divided into an add-on aliskiren group and an ARB
monotherapy group. The primary outcomes were a decline in glomerular filtration rate (GFR) and a reduction in
urinary protein-to-creatinine ratio at six months.
Results: The baseline characteristics of the two groups were similar. Aliskiren 150 mg daily reduced the urinary
protein-to-creatinine ratio by 26% (95% confidence interval, 15 to 37%; p < 0.001). The decline in GFR was smaller in
the add-on aliskiren group (−2.1 vs. -4.0 ml/min, p = 0.038). Add-on aliskiren had a neutral effect on serum
potassium in the non-DM CKD patients. In subgroup analysis, the proteinuria-reducing effect of aliskiren was more
prominent in patients with a GFR less than 60 ml/min, and in patients with a urinary protein-to-creatinine ratio
greater than 1.8. The effect of aliskiren in retarding the decline in GFR was more prominent in patients with
hypertensive nephropathy than in those with glomerulonephritis.
Conclusion: Add-on direct renin inhibitor aliskiren (150 mg daily) safely reduced proteinuria and attenuated the
decline in GFR in the non-DM CKD patients who were receiving ARBs.
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The pathogenesis of chronic kidney disease is multifactor-
ial, and the renin-angiotensin aldosterone system (RAAS)
is known to play an important role. The RAAS is the best
known regulator of blood pressure (BP), fluid and electro-
lyte balance through coordinated effects on the heart,
blood vessels, and kidneys [1]. When over-activated, the* Correspondence: syli@vghtpe.gov.tw
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reproduction in any medium, provided the orRAAS activates a number of pathways and contributes to
the onset and progression of chronic renal damage [2].
Proteinuria is one of the most common findings in chronic
kidney disease (CKD) [3]. The amount of urine protein is
positively associated with glomerulopathy and tubulointer-
stitium damage, and is the strongest prognostic factor for
renal outcomes in CKD patients [4,5]. Inhibition of the
RAAS by angiotensin-converting enzyme (ACE) inhibitors
or angiotensin II receptor blockers (ARBs) prevents the
progression of CKD in both diabetic and non-DM patients
[6-12]. However, in patients with vascular disease or high
risk diabetes, dual RAAS inhibition through a combination
of ACE inhibitors and ARBs is associated with moretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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monotherapy, as shown by the ONTARGET trial [12]. The
ALTITUDE clinical trial attempted to evaluate the potential
renoprotective effect of the add-on direct renin inhibitor
(DRI) aliskiren in high risk type 2 DM patients who were
already taking ACE inhibitors or ARBs, [13] however the
trial was terminated early because of adverse events. These
two clinical trials clearly indicated that dual RAAS inhib-
ition is not suitable for high risk type 2 DM patients. In
contrast, the effect of dual RAAS inhibition in non-DM
patients was still unclear. Although the use of add-on DRIs
has been shown to be renoprotective in various animal
models of non-DM kidney disease, [12,14-17] the clinical
implications are still unclear. The aim of current study,
therefore, was to evaluate the potential renoprotective effect
of the add-on direct renin inhibitor aliskiren in non-DM
CKD patients who were already receiving ARB treatment.Methods
Study population
This retrospective study was approved by the Institutional Re-
view Board of Taipei Veterans General Hospital. We enrolled
patients who were included in the chronic kidney disease care
program at Taipei Veterans General Hospital between March
1, 2010 and April 30, 2011. The CKD care program was
launched by the Taiwan Health Promotion Bureau [18]. This
program organizes nephrologists, renal nurses and dieticians
into a multidisciplinary team to care for CKD patients with
the goals of education and clinical protocols. Every patient
undergoes regular follow-up visits with clinical evaluation, la-
boratory examinations, nursing and dietary education every
1–3 months. The CKD care program improves the quality of
pre-ESRD care and reduces medical costs [19].Inclusion and exclusion criteria
Patients in the CKD care program who were hypertensive,
older than 18 years, had non-DM CKD and proteinuriaFigure 1 Patient selection flowchart.(defined by a spot urinary protein-to-creatinine ratio
of >300 mg per gram), and had been taking ARBs for more
than 90 days were enrolled. The exclusion criteria were
known diabetes mellitus, a urinary protein-to-creatinine
ratio of more than 3500 mg per gram, an estimated glom-
erular filtration rate (GFR) of less than 15 ml per minute
per 1.73 m2 of body-surface area, [20] chronic urinary-
tract infections, a serum potassium level greater than
6.0 mmol per liter at the time of enrollment, and kidney
transplant recipients. Patients who received add-on aliski-
ren 150 mg daily were defined as the aliskiren group, and
the remainders were defined as the ARB monotherapy
group. In the aliskiren group, patients who had not been
taking aliskiren for more than 90 days were also excluded.
Measurement of urine protein and renal function
The patients were examined initially and at 8, 16, and
24 weeks. Blood pressure, concomitant medications, the
results of laboratory tests, and urinary protein-to-creatinine
ratios were assessed at each visit. The urinary protein con-
centration was determined by immunoturbidimetry, and
the creatinine concentration was determined by means of
the Jaffe reaction. The Modification of Diet in Renal Disease
(MDRD) formula was used to estimate the glomerular filtra-
tion rate [20]. All of the other laboratory variables were also
measured centrally in a CAP qualified laboratory. The pri-
mary outcome was the percentage reduction in the urinary
protein-to-creatinine ratio and the secondary outcome was
the eGFR decline from baseline to the end of follow-up.
Statistical analysis
Normally distributed continuous data are expressed as
means± standard deviations. Numeric data with non-normal
distributions are expressed as medians and interquartile
ranges. To compare the parameters among each group,
Pearson χ2 tests were carried out for categorical variables,
and the independent t-test and Mann–Whitney U test were
used for parametric and nonparametric continuous variables,
Table 1 Baseline patient characteristics
Characteristic Aliskiren+ARB Group ARB Group P value
N=57 N=132
Demographic
Age 63.9 ± 19.3 66.5 ± 15.4 0.367
Male gender 61.4% (n= 35) 68.9% (n= 91) 0.313
Clinical
Body-mass index 24.8 ± 3.9 25.2 ± 3.7 0.548
Mean sitting blood pressure-mmHg
Systolic 134.9 ± 16.6 131.0 ± 14.0 0.123
Diastolic 77.2 ± 10.8 77.4 ± 10.5 0.135
Urine protein-to-creatinine ratio 1.84 (0.89 ~ 2.77) 1.81 (0.84 ~ 2.78) 0.723
Estimated glomerular filtration rate ml/min/1.73 m2 50.9 ± 31.1 42.5 ± 19.9 0.062
Hemoglobin (g/liter) 12.0 ± 1.9 11.8 ± 1.9 0.525
Chronic kidney disease stage 0.173
Stage I 10.5% (n= 6) 4.5% (n = 6)
Stage II 17.5% (n= 10) 7.6% (n = 10)
Stage IIIA 14.0% (n= 8) 23.5% (n= 31)
Stage IIIB 28.1% (n= 16) 36.4% (n= 48)
Stage IV 29.8% (n= 17) 28.0% (n= 37)
Etiology 0.917
Hypertensive nephropathy 36.8% (n= 21) 34.1% (n= 45)
Chronic glomerulonephritis 43.9% (n= 25) 47.0% (n= 62)
Interstitial nephritis 19.3% (n= 11) 18.9% (n= 25)
Triglycerides (mg/dl) 146.3 ± 100.2 133.0 ± 79.4 0.369
Cholesterol (mg/dl)
Total 198.9 ± 52.4 183.7 ± 45.7 0.062
Low-density lipoprotein 116.4 ± 38.8 112.4 ± 37.7 0.567
High-density lipoprotein 51.8 ± 14.0 48.6 ± 17.3 0.309
Serum potassium (mmol/liter) 4.2 ± 0.5 4.4 ± 0.6 0.037
Antihypertensive drugs received at baseline
Calcium-channel blocker 52.6% (n= 30) 43.9% (n= 58) 0.272
Beta-blocker 21.1% (n= 12) 15.9% (n= 21) 0.393
Diuretic 35.1% (n= 20) 47.0% (n= 62) 0.130
Alpha-blocker 14.0% (n= 8) 5.3% (n = 7) 0.042
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paired T-test and Wilcoxon test were used for parametric
and nonparametric continuous variables, respectively. All
probabilities were two tailed. A p-value less than 0.05 was
considered significant.
Results
Add on aliskiren attenuated urinary protein and decline
in estimated glomerular filtration rate in non-DM CKD
patients
Fifty-seven patients in the aliskiren group and 132 patients
in the ARB monotherapy group were enrolled in this study(Figure 1). Among the enrolled patients, 78.9% took Losar-
tan 160 mg and 21.1% took irbesartan 300 mg daily, there
are no difference between aliskiren and ARB alone group
in ARB type and dosage. The baseline demographic data
including age, sex, mean urinary protein-to-creatinine
ratio, estimated glomerular filtration rate (eGFR), and
blood pressure of the two groups were comparable
(Table 1).
By the end of the study, compared with baseline, there
was no significant change of mean blood pressure be-
tween the two groups (−1.9 mmHg in the aliskiren group
and −1.3 mmHg in the ARB monotherapy group, p=0.802).
Figure 2 Serial change of proteinuria and eGFR in the two groups. In the 6-month study period, add-on aliskiren reduced the urinary
protein-to-creatinine ratio and slowed down the decline in GFR decline. * Compared with the ARB group, Mann–Whitney U test p < 0.05;
# Compared with baseline, paired t test p < 0.05.
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ment had reduced the mean urinary protein-to-creatinine
ratio by 26% (95% confidence interval [CI], 15-37%;
p<0.001), while there was no significant change in the
amount of urine protein in the ARB monotherapy group.
The decline in eGFR was slower in the aliskiren group com-
pared to the ARB monotherapy group (−2.1 vs. -4.0 ml/min,
p=0.038) (Figure 2). With regards to the risk of hyperkale-
mia, add-on aliskiren had a neutral effect on serum potas-
sium. No stroke or myocardial infarction events occurred
during the study period in either group.Subgroup analysis for anti-proteinuric effect and retarded
GFR decline rate
To evaluate the anti-proteinuric effect of aliskiren in differ-
ent patient populations, we performed subgroup analysis
stratified by gender, baseline eGFR and urine protein. The
proteinuria-reducing effect of add-on aliskiren was more
prominent in males, and in patients with a GFR less than
60 ml/min. Aliskiren had an anti-proteinuric effect in
non-DM CKD patients regardless of the urinary protein
amount, but the effect was more prominent in patients
with heavier proteinuria (Figure 3). In subgroup analysis for
a decline in eGFR, add-on aliskiren retarded the decline in
GFR in patients with hypertensive nephropathy (p=0.037)
but not in patient with glomerulonephritis ( p= 0.40).Discussion
In diabetic and non-DM nephropathy, blocking the RAAS
is the mainstay of therapy to prevent progression of renal
disease [21,22]. ACE inhibitors and ARB have been shown
to have a renoprotective effect and reduced morbidity and
mortality in patients with chronic kidney disease [22,23]
However, the strategy of dual RAAS inhibition seems to
have different clinical impacts in diabetic and non-diabetic
CKD patients. In high risk and type 2 diabetic CKD
patients, a combination of ACE inhibitors and ARBs is
associated with more adverse renal events [12]. Although
add-on DRIs have been shown to reduce urinary protein in
DM nephropathy patients who are receiving ARBs, [24] a
large-scale clinical trial evaluating the effect of add-on DRI
aliskiren 300 mg in high risk DM patients who were taking
ACI inhibitors or ARBs [13] was terminated early because
of increased adverse events, including non-fatal stroke,
hypotension, hyperkalemia and renal complications. How-
ever, the potential renoprotective effect of dual RAAS in-
hibition has not been investigated in non-DM CKD
patients. In the current study, we found that add-on DRI
aliskiren 150 mg daily safely reduced proteinuria and atte-
nuated the decline in GFR in non-DM CKD patients who
were already taking ARBs.
The major difference between the ALTITUDE and the
current study are the patient population and the dosage of
aliskiren. ALTITUDE study included patients taking ACE
Figure 3 Subgroup analysis for the anti-proteinuric effect of aliskiren. The anti-proteinuric effect of add-on aliskiren was analyzed by
gender, baseline eGFR and proteinuria.
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not. Because ACE inhibitor related cough is prevalent in
Asians, most patients who need RAAS inhibition receive
ARBs rather than ACE inhibitors in our CKD program,
thus, we enrolled patients taking ARBs in current study. In
Taiwan, the medical expenditure is paid by National Health
Insurance Program, which covers 99.9% Taiwanese popula-
tion. Currently, aliskiren can be claimed 150 mg (1 tablet)
daily. In contrast, patients in the ALTITUDE trial took alis-
kiren 300 mg daily, and have a higher possibility of hyper-
kalemia and other side effects.
Similar with previous studies on diabetic nephropathy,
[25,26] our results showed that the proteinuria reducing ef-
fect of add-on aliskiren was more prominent in the high risk
group. We also found that the anti-proteinuric effect was
more prominent in patients with an eGFR of less than 60
ml/min, and in patients with a urinary protein-to-creatinineratio greater than 1.8. In addition, we found that add-on alis-
kiren attenuated the decline in GFR in hypertensive nephro-
pathy patients. Although not reaching statistical significance,
our results suggest that add-on aliskiren may have a greater
renoprotective effect in early stage CKD patients (GFR>60
ml/min and not profound proteinuria). There was no signifi-
cant change in mean blood pressure after add-on aliskiren
(p=0.263), indicating that add-on DRIs have a renoprotec-
tive effect in non-DM CKD patients beyond a blood pres-
sure lowering effect. This finding was also confirmed in
several non-DM CKD animal models [14,27,28]. In the
AVOID trial, the reduction in systolic blood pressure was
only 2 mmHg after add-on aliskiren treatment in the study
group.In ONGARTET study, combine RAAS blockade also
has marginal effect on the reduction of blood pressure. The
patients in the current study took half of the dosage of alis-
kiren than the patients in the AVOID study. This may
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effect in our study. Although renin inhibitor monotherapy
provides a dose-dependent BP lowering effect, [29] our
study and the AVOID trial showed that add-on aliskiren in
CKD patients receiving ARBs had a lesser effect on blood
pressure.
The renoprotective effect of add-on aliskiren in patients
with non-DM CKD has been evaluated in clinical settings
in several studies, however all have had limitations. With-
out a control group, Lopez et al. and Tang et al. demon-
strated that add-on aliskiren reduced urinary protein in
kidney transplant recipients (n=12) and immunoglobulin
A nephropathy patients (n=25), respectively [30] [31]. A
prospective trial conducted by Tsukasa Nakamura et al.
found that combination therapy with aliskiren and ARBs
decreased proteinuria in non-DM CKD patients more ef-
fectively than monotherapy alone, however their findings
did not reach statistical significance due to the limited
number of patients (n=12 in each group) [32]. By studying
189 non diabetic CKD patients, the present study clearly
shows that aliskiren reduced proteinuria in patients with
non-DM chronic kidney disease who were receiving ARBs.
Add-on aliskiren (150 mg daily) for six months reduced the
mean urinary protein-to-creatinine ratio by 26%.
There are several limitations to the current study. First, it
was not a randomized prospective control trial, and the
results may have been biased by patient selection and data
retrieval. Second, the 6-month study period was not long
enough to reveal uncommon side effects. Third, plasma
renin activity was not examined in our study, thus, it is un-
known whether changes of plasma renin activity are corre-
lated with the renoprotective effect of aliskiren. Even with
these limitations, we believe our results are reliable and sug-
gest important clinical implications. The patients enrolled in
this study were selected from a registered CKD program,
with frequent follow-up visits and the best clinical care, and
their medical data were complete. To the best of our know-
ledge, the current study is the largest scale study to evaluate
the effect of an add-on direct renin inhibitor in non-DM
CKD patients.Conclusion
In conclusion, we found that add-on aliskiren (150 mg daily)
in non-DM CKD patients already receiving ARBs safely
reduced proteinuria and attenuated the decline in GFR. The
anti-proteinuric effect was more prominent in patients with
an estimated glomerular filtration rate less than 60 ml/min,
and in patients with a urinary protein-to-creatinine ratio
greater than 1.8. Further prospective studies are necessary to
confirm these findings.Competing interest
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